Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingMETXF 14 Debt-to-Equity is 0.04 as of May. 2026, which is 20% below its 10-year median of 0.05. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 956 Biotechnology companies, ME Therapeutics Holding ranks better than 75.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ME Therapeutics Holding's Debt-to-Equity or its related term are showing as below:
METXF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.47 Med: 0.05 Max: 0.11
Current: 0.04
During the past 4 years, the highest Debt-to-Equity Ratio of ME Therapeutics Holding was 0.11. The lowest was -1.47. And the median was 0.05.
METXF's Debt-to-Equity is ranked better than 75.1% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs METXF: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
ME Therapeutics Holding Debt-to-Equity Related Terms
ME Therapeutics Holding Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
METXF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, ME Therapeutics Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ME Therapeutics Holding (METXF) has a Debt-to-Equity of 0.04 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ME Therapeutics Holding and its competitors. This is 20% below median its historical median of 0.05. According to the industry distribution chart, ME Therapeutics Holding ranks #238 out of 956 companies in the Biotechnology industry, placing it in the top 24.9%.
Is ME Therapeutics Holding's Debt-to-Equity too high?
ME Therapeutics Holding's current Debt-to-Equity of 0.04 is 20% below median its 10-year median of 0.05. The Biotechnology industry median Debt-to-Equity is 0.16. ME Therapeutics Holding's value of 0.04 is 75% below this industry median. Based on the distribution chart, ME Therapeutics Holding ranks #238 out of 956 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #238 out of 956 companies for Debt-to-Equity. This places ME Therapeutics Holding in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. ME Therapeutics Holding's value of 0.04 is 75% below this benchmark. While the company's 10-year median is 0.05 vs. the industry median of 0.16, ME Therapeutics Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ME Therapeutics Holding's current Debt-to-Equity of 0.04 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ME Therapeutics Holding and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ME Therapeutics Holding's current Debt-to-Equity is 0.04, which is 20% below median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current Debt-to-Equity of 0.04. The current Debt-to-Equity is 0.04, which is 20% below median its 10-year median of 0.05 and 75% below the Biotechnology industry median of 0.16. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current Debt-to-Equity is 0.04 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for METXF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
METXF has been successfully added to your 
